The press conference of the joint prevention and control mechanism of the State Council introduces the research and development of drugs and vaccines. Some vaccines are expected to enter clinical research in April.

At the press conference of the State Council's joint prevention and control mechanism, relevant persons in charge of the Ministry of Science and Technology and the National Health Commission introduced the development of medicine and other related situations on the progress of research and development.

Some scholars say that the mutation of the new coronavirus will have an impact on vaccine development? Zhou Qi, deputy secretary-general of the Chinese Academy of Sciences and academician of the Chinese Academy of Sciences, introduced that the mutations in the virus seen so far have not affected drug development and the preparation of antibodies and vaccines. We are actively observing the degree of variation of the virus and actively layout related scientific research projects.

Talking about the new progress in the research and development of new crown pneumonia drugs, Sun Yanrong, deputy director of the Biological Center of the Ministry of Science and Technology, said that the results of chloroquine phosphate, Chinese medicine and convalescent plasma are gradually entering the diagnosis and treatment program. A large-scale clinical study of Fapravir is underway in Wuhan.

Zhou Qi, coronavirus infection may cause a storm of inflammatory factors, resulting in multiple organ failure and even life-threatening. Basic research scientists at the University of Science and Technology of China have tested that a typical factor called "interleukin 6" is the direct cause of the storm of inflammatory factors. The drug that blocks interleukin 6 is the drug tocilizumab. "It has a specific blocking effect on interleukin-6. In the initial study, 20 patients, including 19 severe patients and 1 critically ill patient, had a drop in temperature within one day. Within two weeks, 19 patients were discharged from the hospital and 1 critically ill patient became a critically ill patient." Zhou Qi revealed that tocilizumab has now carried out clinical research in 14 designated hospitals in Wuhan. As of March 5, 272 critically ill patients have been treated with tocilizumab.

When talking about the clinical trial effect of raltegravir, sun Yanrong responded that the drug launched two clinical studies in China at the beginning of last month, one for severe patients and one for patients with mild and ordinary diseases. "These two studies use the method of double-blind research, because there is no formal unblinding, so at present, there is no clear result of the research group, and its effectiveness still needs to be expected."

When can I use a qualified vaccine? Zheng Zhongwei, director of the National Health Commission's Medical and Health Science and Technology Development Research Center, introduced that the research and research team has set up a special vaccine research and development class to promote vaccine research along five technical routes. At present, the five technical routes are steadily advancing, and it is expected that some vaccines will be able to enter clinical research or emergency use in April. "The new coronavirus is a new virus, so vaccine development should also continue to explore and deepen understanding." Zheng Zhongwei said.

When talking about the progress of emergency research on testing reagents, Cheng Jing, an academician of the Chinese Academy of Engineering and a professor at the Tsinghua University School of Medicine, introduced that so far, 7 projects have been approved by the State Food and Drug Administration for emergency approval and officially entered the clinic. Among the seven detection reagents, in terms of nucleic acid detection, the latest approved kit based on constant temperature amplification chip technology can quickly detect a variety of common respiratory viruses together, and only 1.5 hours to complete all the tests, and quickly distinguish which patients are infected by the new coronavirus virus, which patients are infected by other viruses, etc.